Independent predictors of cardiovascular risk in polycystic ovarian syndrome

References

• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107–2111.
   PubMed Web of Science ®Google Scholar
• Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84:3110–3116.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24:2286–2292.
   PubMed Web of Science ®Google Scholar
• Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11:23–28.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006;1092:175–186.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SM, Ghosh M. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010;23:158–161.
   PubMed Web of Science ®Google Scholar
• Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, Marber MS, Norman RJ, Horowitz JD. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009;204:509–514.
   PubMed Web of Science ®Google Scholar
• Trakakis E, Balanika A, Baltas C, Loghis C, Simeonidis G, Vaggopoulos V, Papakonstantinou O, Gouliamos A, Salamalekis G, Kassanos D. Hemodynamic alterations and wall properties in large arteries of young, normotensive, and non-obese women with polycystic ovary syndrome. J Endocrinol Invest 2008;31:1001–1007.
   PubMedGoogle Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Fodor JG, Frohlich JJ, Genest JJ Jr., McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162:1441–1447.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357–1361.
   PubMed Web of Science ®Google Scholar
• Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009;55:219–228.
   PubMedGoogle Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481–2485.
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes-2007. Diabetes Care 2007;30:S4–S41.
   PubMedGoogle Scholar
• Gokcel A, Baltali M, Tarim E, Bagis T, Gumurdulu Y, Karakose H, Yalcin F, Akbaba M, Guvener N. Detection of insulin resistance in Turkish adults: a hospital-based study. Diabetes Obes Metab 2003;5:126–130.
   PubMed Web of Science ®Google Scholar
• Karakas SE, Kim K, Duleba AJ. Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome. Diabetes Care 2010;33:887–893.
   PubMedGoogle Scholar
• Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, Muggeo M, Moghetti P. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol 2009;161:737–745.
   PubMed Web of Science ®Google Scholar
• Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet 2010;281:1009–1014.
   PubMed Web of Science ®Google Scholar
• Karadeniz M, Erdoğan M, Tamsel S, Zengi A, Alper GE, Ca?layan O, Saygili F, Yilmaz C. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes 2008;116:231–235.
   PubMed Web of Science ®Google Scholar
• Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23:505–510.
   PubMed Web of Science ®Google Scholar
• Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G, Schöfl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525–532.
   PubMed Web of Science ®Google Scholar
• Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009;26:163–170.
   PubMed Web of Science ®Google Scholar
• Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001;54:447–453.
   PubMed Web of Science ®Google Scholar
• Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93: 470–476.
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts 2009;2:26–35.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.
   PubMed Web of Science ®Google Scholar
• Espinos-Gomez JJ, Corcoy R, Calaf J. Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:199–204.
   PubMed Web of Science ®Google Scholar
• Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabet Med 2010;27:498–515.
   PubMed Web of Science ®Google Scholar